Combination 'Epigenetic' Therapy May Restore Anti-Cancer Gene Activity In Late-Stage Lung Cancer Patients
A new type of therapy aimed at reversing the gene-silencing that promotes cancer-cell growth has shown promising results in a small clinical trial conducted by researchers at the Johns Hopkins Kimmel Cancer Center.
Del Mar Pharmaceuticals Initiates Glioblastoma Clinical Trial
DelMar Pharmaceuticals today announced the initiation of the Company's planned clinical trial with its lead drug candidate, VAL-083, for the treatment of refractory glioblastoma multiforme (GBM).
Positive Phase III Data On Bayer’s Investigational Drug Alpharadin Show Significant Increase In Overall Survival
Bayer HealthCare Pharmaceuticals recently announced positive data on its investigational drug Alpharadin (radium-223 chloride) from the Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial.
Novartis Study Showed ACZ885 Provided Substantial Symptom Relief In 84% Of Patients With The Most Serious Form Of Childhood Arthritis
Novartis announced recently positive results of the first pivotal Phase III trial of ACZ885 (canakinumab) in patients with systemic juvenile idiopathic arthritis (SJIA), a rare and serious childhood auto-inflammatory disease.
RXi Pharmaceuticals Provides Positive NeuVax™ Phase 3 Clinical Trial Update
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, today announced a clinical trial update on its lead program, NeuVax™ (E75 peptide vaccine with GM-CSF adjuvant), a cancer immunotherapy targeted for low-to-intermediate HER2 expressing breast cancer patients not eligible for trastuzamab (Herceptin®).
Aeterna Zentaris Announces Completion Of Patient Recruitment For Phase 3 Trial With Perifosine In Refractory Advanced Colorectal Cancer
Aeterna Zentaris Inc (the "Company") recently announced the completion of patient recruitment for the ongoing Phase 3 trial with perifosine in refractory advanced colorectal cancer.
GSK And Theravance Announce Results Of Two Pivotal Phase III Studies For Relovair In COPD
GlaxoSmithKline (GSK) and Theravance, Inc. recently announced the results of two pivotal 6-month efficacy and safety phase III studies of Relovair for patients with chronic obstructive pulmonary disease (COPD).
NIH Stops Clinical Trial On Combination Cholesterol Treatment
The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has stopped a clinical trial studying a blood lipid treatment 18 months earlier than planned.
Collaborative To Speed Clinical Research And Reduce Costs
The Partnership to Advance Clinical electronic Research (PACeR), a broad-based health care collaborative, aims to make clinical trials faster and less expensive by identifying potential candidates more efficiently and enhancing protocol modeling and data collection.
Radius Announces Closing Of $91M Financing To Advance BA058 Injection Into Phase 3 Osteoporosis Study
Radius Health, Inc. (“Radius”) today announced that the company has raised approximately $91M in its third financing round, including $66M in equity financing and a commitment by GE Capital, Healthcare Financial Services and Oxford Finance LLC to a $25 million multidraw term loan facility.